Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0086)
Name
Vorinostat
Synonyms
Vorinostat; 149647-78-9; SAHA; suberoylanilide hydroxamic acid; Zolinza; N-hydroxy-N'-phenyloctanediamide; N1-hydroxy-N8-phenyloctanediamide; Suberanilohydroxamic acid; MK-0683; MK0683; Octanediamide, N-hydroxy-N'-phenyl-; Vorinostat (SAHA, MK0683); N'-hydroxy-N-phenyloctanediamide; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; Vorinostat (SAHA); CCRIS 8456; N-Hyrdroxy-N'-phenyloctanediamide; NSC-701852; SHH; C14H20N2O3; CHEMBL98; MFCD00945317; NSC-748799; NSC-759852; 58IFB293JI; DTXSID6041133; CHEBI:45716; N1-hydroxy-N8-phenyl-octanediamide; WIN64652; NSC701852; SAHA cpd; NCGC00168085-01; NCGC00168085-02; Vorinostat [USAN]; Zolinza (TN) (Merck); N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; DTXCID4021133; Vorinostat MSD; SMR000486344; Zolinza (TN); CAS-149647-78-9; SR-05000000373; Vorinostat (JAN/USAN); Vorinostat [USAN:INN]; MK 0683; vorinostatum; UNII-58IFB293JI; SKI390; HSDB 7930; 4lxz; Vorinostat(SAHA); Zolinza; SAHA; Vorinostat - SAHA; SAHA, Suberoylanilide hydroxamic acid; 1zz1; VORINOSTAT [MI]; SW-064652; VORINOSTAT [INN]; VORINOSTAT [JAN]; 8-(hydroxyamino)-8-oxo-N-phenyl-octanamide; VORINOSTAT [VANDF]; cid_5311; SCHEMBL9018; VORINOSTAT [MART.]; VORINOSTAT [WHO-DD]; Suberoylanilidehydroxamic Acid; MLS001065855; MLS006011941; n-hydroxy-n-phenyloctanediamide; GTPL6852; VORINOSTAT [ORANGE BOOK]; BDBM19149; Vorinostat (SAHA; MK0683); SUBERANILOHYDROXAMINIC ACID; 1t69; N-hydroxy-N''-phenyloctanediamide; BCPP000018; HMS2219L20; HMS3264D20; HMS3327C12; HMS3426G03; HMS3650D09; HMS3654G11; HMS3715E22; HMS3745M03; Pharmakon1600-01502267; BCP01858; EX-A2745; SAHA, >=98% (HPLC); Vorinostat,SAHA,Zolinza,MK-0683; Tox21_112605; Tox21_113623; Vorinostat,CAS:149647-78-9; HB1396; NSC748799; NSC759852; Octanediamide, N1-hydroxy-N8-phenyl; s1047; SK1390; AKOS015966648; Octanediamide, N1-hydroxy-N8-phenyl-; Tox21_112605_1; AC-1923; CCG-208659; CS-0589; DB02546; DG-0025; NSC 701852; NSC 748799; NSC 759852; SB17319; Suberoylanilide hydroxamic acid (SAHA); NCGC00168085-03; NCGC00168085-04; NCGC00168085-05; NCGC00168085-13; BP-25652; BP-30216; BV164560; HY-10221; SY009383; AM20030018; FT-0650593; H1388; SW199536-4; EC-000.2057; D06320; EN300-120641; AB00375377-07; AB00375377-08; AB00375377-09; AB01644613_25; A808935; Q905901; Vorinostat, SAHA, suberoylanilide hydroxamic acid; SR-05000000373-2; SR-05000000373-6; SR-05000000373-8; W-201327; BRD-K81418486-001-01-2; BRD-K81418486-001-10-3; BRD-K81418486-001-12-9; BRD-K81418486-001-13-7; BRD-K81418486-001-17-8; BRD-K81418486-001-18-6; Z1530532755; N-Hydroxy-N inverted exclamation mark -phenyloctanediamide; 1227736-21-1

    Click to Show/Hide
Structure
Formula
C14H20N2O3
IUPAC Name
N'-hydroxy-N-phenyloctanediamide
Canonical SMILES
C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
InChI
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChIKey
WAEXFXRVDQXREF-UHFFFAOYSA-N
PubChem CID
5311
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
Response regulation The combined effects of vorinostat with salazosulfapyridine (SASP) depend on the accumulation of ROS caused by a decrease in intracellular GSH levels in breast adenocarcinoma, possibly due to SASP-mediated inhibition of xCT. xCT (coded by the SLC7A11 gene), a light chain subunit of the glutamate-cystine antiporter system Xc(-).
References
Ref 1 xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner. Cancers (Basel). 2020 Mar 30;12(4):827. doi: 10.3390/cancers12040827.